ATTR resulting in severe and permanent peripheral nerve damage, and manifested through symptoms that include tingling and numbness in legs and feet, difficulty walking, limb weakness and pain. Polyneuropathy is also known as peripheral neuropathy.

Intellia’s first therapeutic candidate, NTLA-2001, is being studied in the clinic as a single-course treatment for hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN).